PR Newswire
NEWARK, Calif., Nov. 30, 2020
NEWARK, Calif. , Nov. 30, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) and Corporate update at 8:30 a.m. EST on December 9, 2020 . The call will include the Protagonist management team and Andrew Kuykendall , M.D., an investigator in the PTG-300 Phase 2 study and a member of the Department of Malignant Hematology at the Moffitt Cancer Center.
To access the live call, dial 1-844-515-9178 (U.S./ Canada ) or 1-614-999-9313 (international) and refer to conference ID number 8794865. A live and archived webcast will also be accessible in the Investors section of the Company's website at www.protagonist-inc.com .
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. In addition to PTG-200, two oral peptide interleukin-23 receptor antagonist candidates from a collaboration with Janssen Biotech, Inc., are in development and have been selected for advancement into clinical studies. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California . For further information, please visit www.protagonist-inc.com .
View original content to download multimedia: http://www.prnewswire.com/news-releases/protagonist-to-host-conference-call-and-webcast-to-provide-a-research-update-on-december-9-2020-301180069.html
SOURCE Protagonist Therapeutics, Inc.
